Q-omics provides the consensus-scored TYK2 profile across patient tissues and cancer cell-line models. TYK2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TYK2 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, TYK2 RNA expression shows 20,158 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, and ACC as cancer lineages where TYK2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TYK2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TYK2 survival associations across molecular data types. TYK2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (12) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TYK2 RNA expression–survival associations across cancer types. High TYK2 expression shows unfavorable associations in ACC, KICH and KIRC, but favorable associations in HNSC, PAAD and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TYK2 RNA expression.
This table summarizes TYK2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TYK2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TYK2 shows higher tumor expression in HNSC, KIRC, COAD, LIHC, BLCA and KIRP. The HNSC box plot shows higher TYK2 RNA expression in tumor versus normal tissue (log2 FC = +1.071, t-test p < 0.001).
This table shows molecular features associated with TYK2 in patient tissues and cancer cell lines. In patient samples, TYK2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TYK2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and UPPER_AERODIGESTIVE_TRACT.
